Core Insights - Turn Therapeutics has launched a comprehensive communications initiative aimed at enhancing engagement with shareholders and the healthcare community, which includes a recurring webinar series and a Founder Blog by CEO Bradley Burnam [1][2]. Company Overview - Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases. The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [3]. Communications Initiative - The initiative includes a webinar series that will cover ongoing programs, strategic milestones, and upcoming developments, with the first session scheduled for October 22, 2025, at 2:00 PM ET [2][3]. - The Founder Blog will provide updates on company progress, research insights, and perspectives on growth and innovation, with further details to be announced [2]. Commitment to Public Health - Turn Therapeutics is also pursuing global health initiatives, particularly in thermostable vaccine delivery, aimed at serving underserved areas worldwide, reflecting the company's commitment to public health innovation [3].
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025